Compositions and methods for the treatment or prevention of heart failure

19-09-2023 дата публикации

Номер:

US0011760987B2

Автор: H. Kirk Hammond, Mei Hua Gao, Ngai Chin Lai

Принадлежит: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The United States of America as Represented by the Department of Veterans Affairs

Контакты:

Номер заявки: 82-44-1612

Дата заявки: 07-09-2018

CPC - классификация

A A0 A01 A01K A01K2 A01K22 A01K222 A01K2227 A01K2227/A01K2227/1 A01K2227/10 A01K2227/105 A01K226 A01K2267 A01K2267/A01K2267/0 A01K2267/01 A01K2267/03 A01K2267/037 A01K2267/0375 A01K6 A01K67 A01K67/A01K67/0 A01K67/02 A01K67/027 A01K67/0275 A6 A61 A61K A61K4 A61K48 A61K48/A61K48/0 A61K48/00 A61P A61P9 A61P9/A61P9/0 A61P9/04 C C0 C07 C07K C07K2 C07K23 C07K231 C07K2319 C07K2319/C07K2319/0 C07K2319/00 C1 C12 C12N C12N1 C12N15 C12N15/C12N15/8 C12N15/85 C12N15/86 C12N2 C12N27 C12N271 C12N2710 C12N2710/C12N2710/1 C12N2710/10 C12N2710/103 C12N2710/1034 C12N2710/10343 C12N5 C12N5/C12N5/1 C12N5/10 C12N9 C12N9/C12N9/8 C12N9/88 C12Y C12Y4 C12Y40 C12Y406 C12Y406/C12Y406/0 C12Y406/01 C12Y406/010 C12Y406/0100 C12Y406/01001

IPC - классификация

A A0 A01 A01K A01K6 A01K67 A01K67/A01K67/0 A01K67/02 A01K67/027 A6 A61 A61K A61K4 A61K48 A61K48/A61K48/0 A61K48/00 A61P A61P4 A61P43 A61P43/A61P43/0 A61P43/00 A61P9 A61P9/A61P9/0 A61P9/04 C C1 C12 C12N C12N1 C12N15 C12N15/C12N15/8 C12N15/85 C12N15/86 C12N5 C12N5/C12N5/1 C12N5/10 C12N9 C12N9/C12N9/8 C12N9/88

Цитирование НПИ

Chen et al. (2013) Adv. Drug Deliv. Rev., vol. 65(1), 1357-1369. doi:10.1016/j.addr. 2012.09.039.,pp. 1-32.
Gao et al., “Preserved Cardiac Function despite Marked Impairment of cAMP Generation” PLOS One, Sep. 2013, vol. 8, No. 9, p. 1-8.
Hammond et al. (2016) JAMA Cardiol., vol. 1(2), 163-171, doi:10.1001/jamacardio.2016.0008., pp. 1-19.
Hammond et al., “Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure a Randomized Clinical Trial” JAMA Cardiology, May 2016, vol. 1, No. 2, p. 163-171.
Lai et al. (2004) Circulation, vol. 110, 330-336.
Lin et al. (2002) J. Biol. Chem., vol. 277(18), 15721-15728.
Liu et al., “Catalytic mechanism of the adenylyl and guanylyl cyclases: Modeling and mutational analysis” Proc. Natl. Acad. Sci. Dec. 1997, vol. 94, p. 13414-13419.
Matkar et al. (2016) Gene Therapy, vol. 23, 635-648, doi:10. 1038/gt.2016.43.
Rincon et al. (2015) Cardiovascular Research, vol. 108, 4-20, doi:10.1093/cvr/cvv205, pp. 1-17.
Roth et al. (2004) Am. J. Physiol. Heart Circ. Physiol., vol. 287, H172-H177, pp. 1-6.
Scholich et al. (1997) PNAS, vol. 942, 915-2920 Tang et al. (1995) Science, vol. 268 (5218), 1769-1772.
Sunahara et al., “Interaction of Gsa with the Cytosolic Domains of Mammalian Adenylyl Cyclase” The Journal of Biological Chemistry, Aug. 1997, vol. 272, No. 35, p. 22265-22271.
Tang et al. (1995) Science, vol. 268 (5218), 1769-1772.
Tang et al., “Catalytic Mechanism and Regulation of Mammalian Adenylyl Cyclases” Molecular Pharmacology, 1998, vol. 54, p. 231-240.
Thangavel et al., “The C1 and C2 domains target human type 6 adenylyl cyclase to lipid rafts and caveolae” Cell Signal, Feb. 2009, vol. 21, No. 2, p. 301-308.
Yu et al. (2015) Biotech. Adv., vol. 33, 155-164.

Получить PDF